Multiple Myeloma

The AJMC^® Multiple Myeloma compendium is a comprehensive resource for clinical news and expert insights for this cancer.

EHA 2024: Highlights in Multiple Myeloma

Joseph Mikhael, MD, shares insights surrounding key updates in multiple myeloma management as presented at EHA 2024.

Visit Now

Video Interviews

View All

October 24th 2024

MRD: A Game Changer in Multiple Myeloma

October 1st 2024

IMS 2024 Speakers Look Back on Exciting Myeloma Updates

September 26th 2024

Evaluating T-Cell Therapies in First-Line Multiple Myeloma Treatment

September 26th 2024

Creating Equitable AI Models for Multiple Myeloma

September 26th 2024

MRD as a New Paradigm in Myeloma Treatment

August 24th 2024

New CAR T Trial in MM Aims for Triple Receptor Targeting

July 29th 2024

Beyond EHA 2024: Promising Research in Multiple Myeloma to Watch

July 24th 2024

EHA 2024 Highlights: Overcoming Challenges with Bispecific Antibodies in RRMM

July 24th 2024

Future Directions in the Management of Multiple Myeloma

July 19th 2024

ASCO 2024: DREAMM-8 Study of Belantamab Mafodotin, Pomalidomide, and Dexamethasone

Continuing Medical Education

View All

November 21st 2024

ASH Annual Meeting Coverage: Highlighting the Recent Updates in TKI Use in the Treatment of CML – Insights and Application for Managed Care

December 18, 2024 | 1:00 PM & 8:00 PM ET

November 21st 2024

Recent Advances in BCMA-Directed Treatment in Multiple Myeloma: Insights and Application for Managed Care

1.0 Credits / Hematologic Cancer, Oncology

November 21st 2024

Keeping Pace With New Developments in Multiple Myeloma: Updates and Strategies to Optimize Bispecific Antibodies and CAR T-Cell Therapy

1.5 Credits / Oncology, Hematology, Hematologic Cancer

November 21st 2024

Addressing the Gaps and Clinical Challenges in Chronic Lymphocytic Leukemia: Updates and Strategies for Managed Care

1.5 Credits / Hematology, Hematologic Cancer, Oncology

More News

Health disparities word cloud | Image Credit: Colored Lights-stock.adobe.com

October 11th 2024

Delays in Myeloma Oral Therapy Linked to Race, Age

Maggie L. Shaw

Outcomes of interest in this study were time from diagnosis to initial prescription fill for an oral multiple myeloma (MM) medication and time from initial diagnosis to receipt of any treatment for MM.

Surbhi Sidana, MD, MBBS, Stanford University

October 2nd 2024

Isatuximab Approval Highlights Role of Anti-CD38 Antibody in Myeloma Care

Maggie L. Shaw

On September 20, the FDA approved isatuximab plus bortezomib, lenalidomide, and dexamethasone in the first line for patients who have multiple myeloma and are ineligible for transplant.

Multiple myeloma | Image credit: freshidea - stock.adobe.com

September 20th 2024

Varied Types, Levels of Support Needed for Patients With Multiple Myeloma

Julia Bonavitacola

Information on the disease and treatments, assistance with insurance, and transportation are among the types of support needed by patients with multiple myeloma to improve outcomes and overall burden.

Leland Metheny, MD, lead investigator for the phase 1 BAFF CAR T clinical trial, University Hospitals Seidman Cancer Center

September 17th 2024

Bridging Global Treatment Gaps in Relapsed Multiple Myeloma

Maggie L. Shaw

The principal goal of therapies for multiple myeloma, which remains incurable, is to extend progression-free survival, but challenges remain bringing chimeric antigen receptor T-cell therapy to the world, explains Leland Metheny, MD, lead investigator for the phase 1 BAFF CAR T clinical trial, University Hospitals Seidman Cancer Center.

Clinical trial results | Image Credit: Egor-stock.adobe.com

September 12th 2024

D-VRd Boosts MRD Negativity in Transplant-Eligible Multiple Myeloma

Chris Ryan

The FDA approved the quadruplet regimen on July 30 for induction and consolidation therapies in patients with newly diagnoses multiple myeloma who are eligible for autologous stem cell transplant.

Leland Metheny, MD, University Hospitals Seidman Cancer Center

August 30th 2024

Triple-Target CAR T Cells: Benefits and Challenges

Maggie L. Shaw

In part 1 of our interview with Leland Metheny, MD, he explained how a new triple-target chimeric antigen receptor (CAR) T-cell therapy works in multiple myeloma.

August 21st 2024

FDA Issues CRL for Linvoseltamab in R/R Multiple Myeloma

Hayden E. Klein

The complete response letter (CRL) was issued based on a pre-approval inspection at a third-party fill/finish manufacturer.

stem cells | Image Credit: jarun011-stock.adobe.com

August 20th 2024

Second ASCT Extends Survival in Relapsed Multiple Myeloma

Maggie L. Shaw

To continue the response they experienced with a first autologous stem‐cell transplant (ASCT) for their multiple myeloma, patients in this analysis received a second ASCT, with French investigators evaluating their outcomes.

MM treatment | Image Credit: Dzmitry-stock.adobe.com

August 14th 2024

Challenges With Pomalidomide for Patients With Comorbid RRMM, CKD

Maggie L. Shaw

Patients who have comorbid relapsed/refractory multiple myeloma (RRMM) and advanced chronic kidney disease (CKD) are often excluded from clinical trials, leaving treatment gaps for these high-risk patients.

MM blood test | Image Credit: luchschenF-stock.adobe.com

August 6th 2024

Novel Therapies Needed for Older Patients With RRMM

Maggie L. Shaw

Relapsed/refractory multiple myeloma (RRMM) remains an incurable hematologic cancer, often resulting in patients treated with several classes of medications—particularly older patients.

FDA | Image Credit: ra2studio-stock.adobe.com

July 31st 2024

Daratumumab and Hyaluronidase-fihj–Based Quadruplet Regimen Approved in MM

Maggie L. Shaw

Daratumumab/hyaluronidase-fihj plus bortezomib, lenalidomide, and dexamethasone is now approved by the FDA to treat newly diagnosed multiple myeloma (MM) in patients eligible for autologous stem cell transplant.

CAR T in MM | Image Credit: LASZLO-stock.adobe.com

July 25th 2024

Dual-Target CAR T Cells Achieve 100% Response Rate in MM

Maggie L. Shaw

This new analysis examined the investigational chimeric antigen receptor (CAR) T-cell therapy GC012F among patients with newly diagnosed and high-risk multiple myeloma (MM).

Joseph Mikhael, MD, an expert on multiple myeloma

July 19th 2024

EHA 2024: Teclistimab in High-Risk Relapsed/Refractory Multiple Myeloma

Joseph Mikhael, MD

Dr. Mikhael discusses the safety and usefulness of tesclistimab in patients with high-risk refractory multiple myeloma.

Alfred L. Garfall, MD, an expert on multiple myeloma

July 17th 2024

Use of Prophylactic Tocilizumab with Teclistamab: Takeaways from ASCO 2024

Alfred L. Garfall, MD

Alfred L. Garfall, MD, discusses long-term follow-up data from the MajesTEC-1 study presented at ASCO 2024.

July 17th 2024

Treatment in Early Relapse Multiple Myeloma: Takeaways from EHA 2024

Joseph Mikhael, MD

Dr. Mikhael discusses treatment in early relapse of multiple myeloma.

Support group image | Image Credit: Tom Merton/KOTO-stock.adobe.com

July 17th 2024

Myeloma Survivorship Program: Findings and Future Steps

Maggie L. Shaw

Peer and survivorship support are lacking for patients living with multiple myeloma, leading investigators to evaluate a group-focused multidisciplinary intervention that encompassed physical and mental activities.

Multiple myeloma | Image Credit: Felipe Caparrós-stock.adobe.com

July 10th 2024

Final GRIFFIN Trial Data Confirm Daratumumab Benefit Against MM

Maggie L. Shaw

Patient outcomes in this trial were compared between the regimens of lenalidomide, bortezomib, and dexamethasone and daratumumab, lenalidomide, bortezomib, and dexamethasone for use against multiple myeloma (MM).

Interview with Joseph Mikhael, MD, MEd, FRCPC, FACP

July 7th 2024

Game-Changing Strategies for Early-Relapsed Myeloma

Brooke McCormick Maggie L. Shaw

In the final part of our interview with Joseph Mikhael, MD, MEd, FRCPC, FACP, he addresses how patients who experience an early relapse of their multiple myeloma are predisposed to worse outcomes.

AJMC with Dr Suzane Lentzsch | Background image credit: ipopba - stock.adobe.com

July 2nd 2024

Advancements and Challenges in Treating Relapsed/Refractory Multiple Myeloma

Brooke McCormick Maggie L. Shaw

In part 2 of our interview with Suzanne Lentzsch, MD, PhD, Columbia University's College of Physicians and Surgeon, she touches on potential new therapies, important clinical considerations, and treatment challenge for relapsed/refractory multiple myeloma.

multiple myeloma | Image Credit: ibreakstock-stock.adobe.com

June 28th 2024

Ide-Cel Generates Durable Responses in Functionally High-Risk Myeloma

Ariana Pelosci

In April, the FDA approved decabtagene vicleucel (ide-cel) for earlier treatment of relapsed/refractory multiple myleoma.

June 27th 2024

The Tremendous Complexity of Treating RRMM

Brooke McCormick Maggie L. Shaw

In this interview from our coverage of the European Hematology Association 2024 Congress, Joseph Mikhael, MD, MEd, FRCPC, FACP, International Myeloma Foundation, discusses the complex principles that underlie treating multiple myeloma (MM) in the US.

June 21st 2024

Dr Suzanne Lentzsch Highlights Promising Linvoseltamab Results in Treating RRMM

Brooke McCormick

Suzanne Lentzsch, MD, PhD, of Columbia University, presented promising results of linvoseltamab for treating relapsed/refractory multiple myeloma (RRMM) at the European Hematology Association 2024 Congress.

multiple myeloma diagnosis | Image Credit: shidlovski-stock.adobe.com

June 13th 2024

MRD2STOP: Promise in Halting Myeloma Maintenance Therapy

Maggie L. Shaw

One patient died during this study, which used PET/CT, flow cytometry, and next-generation sequencing to define measurable residual disease negativity.

Sarclisa packaging | Image credit: Sanofi

June 4th 2024

IMROZ: Adding Isatuximab to SOC in Transplant-Ineligible Newly Diagnosed Multiple Myeloma Cut Risk of Disease Progression or Death 40%

Mary Caffrey

Combining the anti-CD38 monoclonal antibody with a standard backbone triplet should be the new standard of care for newly diagnosed patients not eligible for transplant, said lead investigator Thierry Facon, MD.

May 24th 2024

Future Indications and Frontline Potential of Cilta-Cel in Multiple Myeloma: Insights From Dr Binod Dhakal

Maggie L. Shaw

In the final part of our interview with Binod Dhakal, MD, lead investigator of the CARTITUDE-4 study, he looks to the future of earlier treatment for relapsed/refractory multiple myeloma.

Raymond Thertulien, MD, PhD | Image credit: LinkedIn

May 20th 2024

Raymond Thertulien, MD, PhD, on How Abnormalities Drive Treatment Choices in Multiple Myeloma

Rose McNulty

MM image | Image Credit: Svetlana-stock.adobe.com

May 15th 2024

CAR T Proves Effective and Safe for Refractory Multiple Myeloma

Maggie L. Shaw

Due to increasing reports of multiple myeloma and the emergence of chimeric antigen receptor (CAR) T-cell therapy as a treatment option, these investigators conducted a comprehensive review of the medical literature on the latest CAR T developments in the MM space.

May 6th 2024

Dr Binod Dhakal: The Importance of Patient Monitoring With Cilta-Cel Treatment

Maggie L. Shaw

In part 2 of our interview with Binod Dhakal, MD, he addresses how CARTITUDE-4 study findings help to advance the clinical understanding of ciltacabtagene autoleucel (cilta-cel) and the importance of vigilance and education on the treatment’s adverse effects.

Binod Dhakal, MD, Medical College of Wisconsin, lead CARTITUDE-4 investigator

April 24th 2024

Dr Binod Dhakal Discusses Game-Changing Cilta-Cel Approval for RRMM

Maggie L. Shaw

Binod Dhakal, MD, associate professor, Medical College of Wisconsin, is lead investigator of the CARTITUDE-4 study, from which data were used by the FDA to approve ciltacabtagene autoleucel (cilta-cel) for patients with relapsed/refractory multiple myeloma (RRMM) who have received at least 1 prior line of therapy.

Janssen image | Image Credit: Sundry Protography - stock.adobe.com

April 23rd 2024

Talquetamab Cost-Effective Breakthrough for RRMM

Maggie L. Shaw

The FDA granted accelerated approval to talquetamab on August 9, 2023, as a treatment option for adult patients with relapsed/refractory multiple myeloma (RRMM) who have failed at least 4 prior lines of therapy.

1 2 3 4 5 6 7 8

...

10 >

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

Do Not Sell My Information

Terms & Conditions

Multiple Myeloma

Latest News

EHA 2024: Highlights in Multiple Myeloma

More News